These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 35159250)
1. Current Status and Challenges of Human Induced Pluripotent Stem Cell-Derived Liver Models in Drug Discovery. Tricot T; Verfaillie CM; Kumar M Cells; 2022 Jan; 11(3):. PubMed ID: 35159250 [TBL] [Abstract][Full Text] [Related]
2. Thinking outside the liver: induced pluripotent stem cells for hepatic applications. Subba Rao M; Sasikala M; Nageshwar Reddy D World J Gastroenterol; 2013 Jun; 19(22):3385-96. PubMed ID: 23801830 [TBL] [Abstract][Full Text] [Related]
3. Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells. Blaszkiewicz J; Duncan SA Genes (Basel); 2022 Mar; 13(4):. PubMed ID: 35456379 [TBL] [Abstract][Full Text] [Related]
4. Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy. Pan Z; Liang P Handb Exp Pharmacol; 2023; 281():209-233. PubMed ID: 37421443 [TBL] [Abstract][Full Text] [Related]
5. Induced Pluripotent Stem Cells as a Tool for Modeling Hematologic Disorders and as a Potential Source for Cell-Based Therapies. Pratumkaew P; Issaragrisil S; Luanpitpong S Cells; 2021 Nov; 10(11):. PubMed ID: 34831472 [TBL] [Abstract][Full Text] [Related]
7. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Chun YS; Chaudhari P; Jang YY Int J Biol Sci; 2010 Dec; 6(7):796-805. PubMed ID: 21179587 [TBL] [Abstract][Full Text] [Related]
8. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases. Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228 [TBL] [Abstract][Full Text] [Related]
9. New lessons learned from disease modeling with induced pluripotent stem cells. Onder TT; Daley GQ Curr Opin Genet Dev; 2012 Oct; 22(5):500-8. PubMed ID: 22749051 [TBL] [Abstract][Full Text] [Related]
10. Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Asgari S; Moslem M; Bagheri-Lankarani K; Pournasr B; Miryounesi M; Baharvand H Stem Cell Rev Rep; 2013 Aug; 9(4):493-504. PubMed ID: 22076752 [TBL] [Abstract][Full Text] [Related]
11. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids. Mun SJ; Ryu JS; Lee MO; Son YS; Oh SJ; Cho HS; Son MY; Kim DS; Kim SJ; Yoo HJ; Lee HJ; Kim J; Jung CR; Chung KS; Son MJ J Hepatol; 2019 Nov; 71(5):970-985. PubMed ID: 31299272 [TBL] [Abstract][Full Text] [Related]
12. Molecular Profiling of Human Induced Pluripotent Stem Cell-Derived Cells and their Application for Drug Safety Study. Matsui T; Miyamoto N; Saito F; Shinozawa T Curr Pharm Biotechnol; 2020; 21(9):807-828. PubMed ID: 32321398 [TBL] [Abstract][Full Text] [Related]
13. Efficient Generation of Functional Hepatocytes from Human Induced Pluripotent Stem Cells for Disease Modeling and Disease Gene Discovery. Kumar S; Curran JE; Williams-Blangero S; Blangero J Methods Mol Biol; 2022; 2549():85-101. PubMed ID: 33772461 [TBL] [Abstract][Full Text] [Related]
14. Preferential Hematopoietic Differentiation in Induced Pluripotent Stem Cells Derived From Human Umbilical Cord Arterial Endothelial Cells. Pei H; Li H; Xu L; Zhang B; Zhang H; Jia Y; Liang L; Xie X; Fan Z; Yang Z; Wang X; Song F; He L; Yue W; Pei X Arterioscler Thromb Vasc Biol; 2023 May; 43(5):697-712. PubMed ID: 36951064 [TBL] [Abstract][Full Text] [Related]
15. A new era of disease modeling and drug discovery using induced pluripotent stem cells. Suh W Arch Pharm Res; 2017 Jan; 40(1):1-12. PubMed ID: 27921262 [TBL] [Abstract][Full Text] [Related]
16. The application of engineered liver tissues for novel drug discovery. Lin C; Ballinger KR; Khetani SR Expert Opin Drug Discov; 2015 May; 10(5):519-40. PubMed ID: 25840592 [TBL] [Abstract][Full Text] [Related]
17. Differentiation of primordial germ cells from induced pluripotent stem cells of primary ovarian insufficiency. Leng L; Tan Y; Gong F; Hu L; Ouyang Q; Zhao Y; Lu G; Lin G Hum Reprod; 2015 Mar; 30(3):737-48. PubMed ID: 25586786 [TBL] [Abstract][Full Text] [Related]
18. Functional Maturation of Induced Pluripotent Stem Cell Hepatocytes in Extracellular Matrix-A Comparative Analysis of Bioartificial Liver Microenvironments. Wang B; Jakus AE; Baptista PM; Soker S; Soto-Gutierrez A; Abecassis MM; Shah RN; Wertheim JA Stem Cells Transl Med; 2016 Sep; 5(9):1257-67. PubMed ID: 27421950 [TBL] [Abstract][Full Text] [Related]
19. Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing. Yin X; Li Q; Shu Y; Wang H; Thomas B; Maxwell JT; Zhang Y J Biomed Sci; 2024 May; 31(1):47. PubMed ID: 38724973 [TBL] [Abstract][Full Text] [Related]
20. Reprogramming of HUVECs into induced pluripotent stem cells (HiPSCs), generation and characterization of HiPSC-derived neurons and astrocytes. Haile Y; Nakhaei-Nejad M; Boakye PA; Baker G; Smith PA; Murray AG; Giuliani F; Jahroudi N PLoS One; 2015; 10(3):e0119617. PubMed ID: 25789622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]